Psychiatry :: FDA approves Risperdal for two psychiatric conditions in children and adolescents
The U.S. Food and Drug Administration approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.